Jiangsu Bioperfectus Technologies Co Ltd (688399) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.007x

Based on the latest financial reports, Jiangsu Bioperfectus Technologies Co Ltd (688399) has a cash flow conversion efficiency ratio of 0.007x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥20.00 Million ≈ $2.93 Million USD) by net assets (CN¥2.97 Billion ≈ $434.25 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Jiangsu Bioperfectus Technologies Co Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)

This chart illustrates how Jiangsu Bioperfectus Technologies Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Jiangsu Bioperfectus Technologies Co Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.

Jiangsu Bioperfectus Technologies Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Jiangsu Bioperfectus Technologies Co Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Eton Pharmaceuticals Inc NASDAQ:ETON	-0.442x
Winner Information Technology Co Inc SHE:300609	-0.010x
Akasha Wira International Tbk JK:ADES	0.056x
Burelle SA PA:BUR	0.159x
Samsung Electro Mechanics Pref KO:009155	0.030x
Elec-Tech International Co Ltd SHE:002005	-0.147x
Chahua Modern Housewares Co Ltd SHG:603615	-0.105x
Beijing Jiaxun Feihong Electrical Co Ltd SHE:300213	0.032x

Annual Cash Flow Conversion Efficiency for Jiangsu Bioperfectus Technologies Co Ltd (2016–2024)

The table below shows the annual cash flow conversion efficiency of Jiangsu Bioperfectus Technologies Co Ltd from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see Jiangsu Bioperfectus Technologies Co Ltd (688399) market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	CN¥3.25 Billion ≈ $475.67 Million	CN¥145.93 Million ≈ $21.35 Million	0.045x	+235.10%
2023-12-31	CN¥3.41 Billion ≈ $498.27 Million	CN¥-113.14 Million ≈ $-16.56 Million	-0.033x	-106.39%
2022-12-31	CN¥3.78 Billion ≈ $552.86 Million	CN¥1.96 Billion ≈ $287.52 Million	0.520x	+33.85%
2021-12-31	CN¥2.54 Billion ≈ $371.16 Million	CN¥985.52 Million ≈ $144.21 Million	0.389x	-30.90%
2020-12-31	CN¥1.66 Billion ≈ $243.57 Million	CN¥935.88 Million ≈ $136.95 Million	0.562x	+437.82%
2019-12-31	CN¥1.02 Billion ≈ $149.37 Million	CN¥106.72 Million ≈ $15.62 Million	0.105x	-60.52%
2018-12-31	CN¥324.10 Million ≈ $47.43 Million	CN¥85.82 Million ≈ $12.56 Million	0.265x	+11.90%
2017-12-31	CN¥260.28 Million ≈ $38.09 Million	CN¥61.59 Million ≈ $9.01 Million	0.237x	+169.80%
2016-12-31	CN¥251.90 Million ≈ $36.86 Million	CN¥22.09 Million ≈ $3.23 Million	0.088x	--

About Jiangsu Bioperfectus Technologies Co Ltd

SHG:688399 China Biotechnology

Market Cap

$739.08 Million

CN¥5.05 Billion CNY

Market Cap Rank

#10619 Global

#3110 in China

Share Price

CN¥60.22

Change (1 day)

-2.48%

52-Week Range

CN¥45.89 - CN¥84.90

All Time High

CN¥419.88